文献速递胃肠动力与功能性疾病

功能性消化不良临床试验中安慰剂治疗反应的相关因素

Factors Associated With Placebo Treatment Response in Functional Dyspepsia Clinical Trials.
PubMed 文献 · Am J Gastroenterol · 2022-12-20

该研究对一项功能性消化不良临床试验中2个被视为涉及安慰剂治疗的组别数据进行二次分析,从心理、临床和生理特征中寻找安慰剂效应的预测因素。结果发现基线症状负荷较高、合并肠易激综合征及Nepean消化不良指数进食/饮水域评分较高可预测更强的安慰剂效应,前两者为独立预测因素并解释13%的胃肠症状评定量表变化方差。

要点

  • 基线功能性消化不良症状负荷较高可预测更强的安慰剂效应(b=-0.101)。
  • 合并肠易激综合征可独立预测更强的安慰剂效应(b=-0.436)。
  • 基线症状负荷与合并肠易激综合征共解释13%的胃肠症状评定量表变化方差。

核心结论

  • 研究结果为试验方法学提供了可操作的见解,可能有助于降低未来功能性消化不良治疗试验中安慰剂效应的幅度。

研究设计与样本

  • 对一项功能性消化不良临床试验数据进行二次分析,使用2个被视为涉及安慰剂治疗的组别。
  • 潜在预测因素来自广泛的患者特征,包括心理、临床和生理特征。

主要发现

  • 对胃肠症状评定量表安慰剂效应更强的预测因素包括基线功能性消化不良症状负荷较高(b=-0.101)、合并肠易激综合征(b=-0.436)及Nepean消化不良指数进食/饮水域评分较高(-0.005)。
  • 基线症状负荷和合并肠易激综合征为独立安慰剂预测因素,解释胃肠症状评定量表变化方差的13%。
  • 焦虑、童年期性虐待、睡眠量和频繁腹痛也被发现是单个症状评分变化的预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Controlling for potential placebo effects is an important aspect of gaining an accurate estimate of how much the therapy alone changes patient symptoms or other end points. When the placebo effect is large, this can lead to only a small fraction of changes seen in the active therapy group being attributed to the therapy itself. This problem has been well studied in some disorders of brain-gut interaction but not in functional dyspepsia where placebo response rates of 40% and higher have been reported. Understanding risk factors for placebo response might lead to changes in trial design that could reduce the magnitude of the problem. This study sought to identify risk factors for the placebo effect in a functional dyspepsia clinical trial with a longer-term aim of suggesting trial design changes that might minimize the problem. METHODS: A secondary analysis of the clinical trial data was undertaken using 2 arms deemed to involve placebo therapy. Potential predictors were drawn from a wide range of patient characteristics including psychological, clinical, and physiological features. RESULTS: Predictors of a stronger placebo effect on the gastrointestinal symptom rating scale included higher functional dyspepsia symptom burden at baseline ( b = -0.101), coexisting irritable bowel syndrome ( b = -0.436), and higher scores on the Nepean Dyspepsia Index eat/drink domain (-0.005). Baseline symptom burden and coexisting irritable bowel syndrome were found to be independent placebo predictors, explaining 13% of the variance in change in gastrointestinal symptom rating scale. Anxiety, childhood sexual abuse, sleep amount, and frequent abdominal pain were also found to be predictors of change in individual symptom scores. DISCUSSION: The findings of this study yield actionable insights into trial methodology that may help to reduce the magnitude of the placebo effect in future functional dyspepsia treatment trials.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jones MP, Guthrie-Lyons L, Sato YA, et al. Factors Associated With Placebo Treatment Response in Functional Dyspepsia Clinical Trials. Am J Gastroenterol. 2022. PMID: 36729385. doi:10.14309/ajg.0000000000002097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。